Press release
Graft Versus Host Disease Market Set to Expand at 8.2% CAGR Through 2034, Driven by a Robust Pipeline | DelveInsight
Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2034
DelveInsight's "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the GvHD market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The GvHD market forecast anticipates a CAGR of 8.2% through 2034 from USD 1.3 billion in 2023. Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market.
Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report also analyzes historical and projected GvHD epidemiology, segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease.
DelveInsight estimates approximately 52K Graft Versus Host Disease cases in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants.
Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2025 to 2034. Current GvHD therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others.
Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases.
DelveInsight's analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others.
Unlock which emerging Graft Versus Host Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
In January 2025, the FDA approved Incyte's and Syndax's Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market.
Furthermore, in March 2025, Signal12 Pharmaceuticals secured FDA alignment for their Phase 3 trial of Pro-ocular, a novel drop-free therapy for ocular graft-versus-host disease, following successful Phase 2 results showing sustained improvements in corneal staining and symptom scores. These recent developments indicate a positive momentum in the GvHD treatment market.
Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight's report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively.
Table of Contents
1. Key Insights
2. Report Introduction
3. GvHD Market Overview at a Glance
4. Executive Summary
5. Key Events
6. GvHD Background and Overview
7. Methodology
8. GvHD Epidemiology and Patient Population
9. GvHDPatient Journey
10. GvHD Marketed Drugs
11. GvHD Emerging Drugs
12. GvHD - 7MM Market Analysis
13. KOL Views
14. GvHD Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Related Reports
Graft versus host disease (GvHD) Pipeline Insight [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, and Amgen among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graft-versus-host-disease-market-set-to-expand-at-82-cagr-through-2034-driven-by-a-robust-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft Versus Host Disease Market Set to Expand at 8.2% CAGR Through 2034, Driven by a Robust Pipeline | DelveInsight here
News-ID: 4078720 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for GvHD
Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022
Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100…
Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The…
Graft Versus Host Disease GvHD Treatment Market Investment Research Report 2016- …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain…
Graft Versus Host Disease GvHD Treatment Market Revenue and Value Chain 2016-202 …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain…
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.
Graft-versus-host disease (GVHD) is a complication that can occur after…
Graft Versus Host Disease (GvHD) Market - Global Industry Analysis 2024
During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a…
